case of drug-induced liver injury (DILI) caused by liraglutide to be reported. We present a case of a 40-year-old Chinese woman who developed acute liver injury with elevated liver enzymes following 2 weeks of liraglutide treatment for T2DM. Causality was assessed using the updated RUCAM scale, yielding a score of 7, indicating probable DILI, and the diagnosis was further confirmed by liver biopsy. Liver enzyme levels normalized after discontinuing the drug and administering liver-protective treatment within 3 weeks. Furthermore, this case report includes a comprehensive review of all published cases of liraglutide-associated DILI, emphasizing the necessity of regular hepatic-biochemistry monitoring in patients receiving GLP-1 receptor agonists such as liraglutide and providing meaningful evidence regarding their hepatotoxic risk.
No takes yet. Share an insight, caveat, or question.
苏芬丽 et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: